95 related articles for article (PubMed ID: 20662411)
1. [Compliance in psychiatry].
Cesková E
Cas Lek Cesk; 2009; 148(10):489-92. PubMed ID: 20662411
[TBL] [Abstract][Full Text] [Related]
2. [Therapeutic alliance, a stake in schizophrenia].
Charpentier A; Goudemand M; Thomas P
Encephale; 2009 Feb; 35(1):80-9. PubMed ID: 19250998
[TBL] [Abstract][Full Text] [Related]
3. Partial compliance in schizophrenia and the impact on patient outcomes.
Llorca PM
Psychiatry Res; 2008 Nov; 161(2):235-47. PubMed ID: 18849080
[TBL] [Abstract][Full Text] [Related]
4. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
Kane JM; Leucht S; Carpenter D; Docherty JP;
J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
[TBL] [Abstract][Full Text] [Related]
5. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
Bret P; Bret MC; Queuille E
Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
[TBL] [Abstract][Full Text] [Related]
6. Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses.
Turner MS; Stewart DW
J Psychopharmacol; 2006 Nov; 20(6 Suppl):20-37. PubMed ID: 17046985
[TBL] [Abstract][Full Text] [Related]
7. Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence.
Barbui C; Kikkert M; Mazzi MA; Becker T; Bindman J; Schene A; Nosè M; Helm H; Thornicroft G; Tansella M
Psychopathology; 2009; 42(5):311-7. PubMed ID: 19672133
[TBL] [Abstract][Full Text] [Related]
8. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.
Goodwin G; Fleischhacker W; Arango C; Baumann P; Davidson M; de Hert M; Falkai P; Kapur S; Leucht S; Licht R; Naber D; O'Keane V; Papakostas G; Vieta E; Zohar J
Eur Neuropsychopharmacol; 2009 Jul; 19(7):520-32. PubMed ID: 19411165
[TBL] [Abstract][Full Text] [Related]
9. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
10. Towards the improvement of compliance: the significance of psycho-education and new antipsychotic drugs.
Gaebel W
Int Clin Psychopharmacol; 1997 Feb; 12 Suppl 1():S37-42. PubMed ID: 9179642
[TBL] [Abstract][Full Text] [Related]
11. [The first long-acting atypical antipsychotic: new milestone in the treatment of schizophrenia].
Faludi G
Neuropsychopharmacol Hung; 2005 Mar; 7(1):22-7. PubMed ID: 16167464
[TBL] [Abstract][Full Text] [Related]
12. Optimisation of long-term treatment in schizophrenia: treating the true spectrum of symptoms.
Kasper S
Eur Neuropsychopharmacol; 2006 Sep; 16 Suppl 3():S135-41. PubMed ID: 16872809
[TBL] [Abstract][Full Text] [Related]
13. Symptom domains of schizophrenia: the role of atypical antipsychotic agents.
Burton S
J Psychopharmacol; 2006 Nov; 20(6 Suppl):6-19. PubMed ID: 17046984
[TBL] [Abstract][Full Text] [Related]
14. The relationship between patient satisfaction and treatment outcomes in schizophrenia.
Chue P
J Psychopharmacol; 2006 Nov; 20(6 Suppl):38-56. PubMed ID: 17046986
[TBL] [Abstract][Full Text] [Related]
15. The case for long-acting antipsychotic agents in the post-CATIE era.
Nasrallah HA
Acta Psychiatr Scand; 2007 Apr; 115(4):260-7. PubMed ID: 17355516
[TBL] [Abstract][Full Text] [Related]
16. Differences of satisfaction with medication between patients with schizophrenia treated with typical antipsychotics and atypical antipsychotics.
Watanabe A; Shibata I; Kato T
Psychiatry Clin Neurosci; 2004 Jun; 58(3):268-73. PubMed ID: 15149292
[TBL] [Abstract][Full Text] [Related]
17. Influences on therapist's decisions for neuroleptic treatment in schizophrenia: the role of characteristics of the patient and the physician.
Franz M; Ranger J; Hanewald B; Gallhofer B; Lay B
Pharmacopsychiatry; 2012 Nov; 45(7):261-8. PubMed ID: 22648306
[TBL] [Abstract][Full Text] [Related]
18. [Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications].
Misdrahi D; Llorca PM; Lançon C; Bayle FJ
Encephale; 2002; 28(3 Pt 1):266-72. PubMed ID: 12091789
[TBL] [Abstract][Full Text] [Related]
19. [What information do patients with schizophrenia have about their illness and treatment?].
Ferreri M; Rouillon F; Nuss P; Bazin N; Farah S; Djaballah K; Gerard D
Encephale; 2000; 26(5):30-8. PubMed ID: 11192802
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.
Fujikawa M; Togo T; Yoshimi A; Fujita J; Nomoto M; Kamijo A; Amagai T; Uchikado H; Katsuse O; Hosojima H; Sakura Y; Furusho R; Suda A; Yamaguchi T; Hori T; Kamada A; Kondo T; Ito M; Odawara T; Hirayasu Y
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):755-60. PubMed ID: 18226436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
